China Biologic Products (CBPO) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of China Biologic Products (NASDAQ:CBPO) from a strong-buy rating to a buy rating in a report released on Thursday morning, BidAskClub reports.

Several other research analysts have also recently issued reports on the company. Credit Suisse Group set a $88.00 price objective on China Biologic Products and gave the stock a hold rating in a research note on Friday, March 8th. ValuEngine upgraded China Biologic Products from a hold rating to a buy rating in a research note on Friday, March 1st. Finally, Jefferies Financial Group cut China Biologic Products from a hold rating to an underperform rating and reduced their price objective for the stock from $67.00 to $62.00 in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $78.00.

Shares of NASDAQ:CBPO remained flat at $$92.70 during trading on Thursday. The stock had a trading volume of 126,291 shares, compared to its average volume of 294,182. China Biologic Products has a 1 year low of $60.08 and a 1 year high of $107.44. The stock has a market capitalization of $3.65 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 4.91 and a beta of 1.28.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. China Biologic Products had a return on equity of 9.54% and a net margin of 27.43%. The firm had revenue of $129.78 million during the quarter, compared to analysts’ expectations of $119.50 million. During the same period last year, the business posted $1.21 earnings per share. Equities analysts expect that China Biologic Products will post 3.78 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Dalton Investments LLC raised its position in China Biologic Products by 51.1% in the first quarter. Dalton Investments LLC now owns 113,851 shares of the biopharmaceutical company’s stock valued at $10,389,000 after purchasing an additional 38,500 shares during the period. Alpine Global Management LLC purchased a new position in China Biologic Products in the first quarter valued at about $480,000. Laurion Capital Management LP purchased a new position in China Biologic Products in the first quarter valued at about $317,000. Parametrica Management Ltd purchased a new position in China Biologic Products in the first quarter valued at about $334,000. Finally, Nikko Asset Management Americas Inc. purchased a new position in China Biologic Products in the first quarter valued at about $4,966,000. Hedge funds and other institutional investors own 37.39% of the company’s stock.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: Are FAANG stocks a good investment?

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.